Clinical trial · Interventional
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT07439653CI-TRIAL-00123379recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TORL-5-700 | Drug | — | UNRESOLVED |
| TORL-5-700 at MTD/RP2D | Drug | — | UNRESOLVED |
| TORL-5-700 at MTD/RP2D in combination with another agent | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Part 1: Monotherapy Dose Escalation
- description
- TORL-5-700 Administered once every three weeks
- interventionNames
- Drug: TORL-5-700
- type
- EXPERIMENTAL
- label
- Part 2: Monotherapy Expansion
- description
- TORL-5-700 at MTD/RP2D Administered once every three weeks
- interventionNames
- Drug: TORL-5-700 at MTD/RP2D
- type
- EXPERIMENTAL
- label
- Part 3: Combination Evaluation
- description
- TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * At least 1 measurable lesion per Lugano criteria. * Tumor tissue is available. * Adequate organ function Exclusion Criteria: * T-cell lymphoma * CLL or SL * Burkitt lymphoma and high-grade B-cell lymphoma * CNS involvement * Peripheral neuropathy \> Grade 2 * Uncontrolled medical conditions * Viral infections
References
Publications (0)
Data not yet available
No reference posted for this study.